Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.


TSX:TH - Post by User

Bullboard Posts
Comment by bfwon Dec 15, 2018 1:02pm
163 Views
Post# 29119842

RE:RE:Forecasting next 5 Quarters

RE:RE:Forecasting next 5 Quarters
Let’s say you are correct.

We’d be looking at 2019 earnings of 38 cents. 2020 earnings would be closer of 75 cents by eyeballing it witj expected growth.

I think the market would pay 20x earnings of the following year with that growth.

So, with a decent market, we could still see $15 next year.

bfw

palinc2000 wrote:
palinc2000 wrote: Spceo..... 
I have made an attempt to forecast the number of US patients and the corresponding EPS for the next 5 Quarters
If anything I think this is conservative 
I presume that you have developed your own model and maybe you could add your projections in red...... 


Average number of patients during the Quarter and corresponding EPS  (38 cents EPS for next year(
 
4thQuarterFY  2018— 350.     .04
 
First QuarterFY  2019- 450.      .055
Second Quarter FY 2019- 600. .075
Third Quarter Fy 2019  - 850    .106
Fourth Quarter FY 2019-1150   .143

This is a post ftom November in which I made an attemt to forecast the progression in number of patients.Of course the actual numbers will for sure differ from the above but I think that they provide a good base to derive reasonable expectations for the average number of patients for 2019


Bullboard Posts